Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Senicapoc - Icagen

Next Previous
Drug Profile

Senicapoc - Icagen

Alternative Names: ICA-17043

Latest Information Update: 11 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Icagen
  • Developer Icagen; Neusentis
  • Class Antianaemics; Small molecules
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Asthma

Highest Development Phases

  • Discontinued Allergic asthma; Exercise-induced asthma; Inflammation; Sickle cell anaemia

Most Recent Events

  • 03 Dec 2024 Vejle Hospital plans a phase II trial for Idiopathic pulmonary fibrosis and Idiopathic pulmonary fibrosis in Denmark and Estonia (PO) in January 2025 (NCT06714123)
  • 30 Jul 2020 Discontinued - Phase-III for Sickle cell anaemia (In adolescents, In adults) in France (PO)
  • 30 Jul 2020 Discontinued - Phase-III for Sickle cell anaemia (In adolescents, In adults) in United Kingdom (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top